NDA 021129 · Viatris
Neurontin
Gabapentin · Oral
Last checked: Nov 19, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Mar 2, 2000
Approved uses
3
Original approval plus efficacy supplements
Registered trials
501
111 Phase 3, 25 recruiting
FAERS reports
364,199
231,729 serious, 34,539 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 12, 2026.
NEURONTIN ® is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy NEURONTIN is indicated for: • Postherpetic neuralgia in adults ( 1 ) • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )
Mechanism: The precise mechanisms by which gabapentin produces its analgesic and antiepileptic actions are unknown. Gabapentin is structurally related to the neurotransmitter gamma-aminobutyric acid (GABA) but has no effect on GABA binding, uptake, or degradation. In vitro studies have shown that gabapentin binds with high-affinity to the α2δ subunit of voltage-activated calcium channels; however, the relationship of this binding to the therapeutic effects of gabapentin is unknown.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 15, 2002 Supplement 10 · Efficacy Letter
- Oct 12, 2000 Supplement 5 · Efficacy Review
- Mar 2, 2000 Original approval · Type 3 - New Dosage Form Other Important Information from FDAReview
1 products under this application
- NEURONTIN · GABAPENTIN 250MG/5ML · SOLUTION, ORAL · Prescription · TE AA
Clinical trials
Interventional ClinicalTrials.gov studies with "Gabapentin" as an intervention, any sponsor and status, largest first.
- A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional SleeplessnessPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00666575 · 2,105 participants (planned) · Start Dec 2004
Drug: Gabapentin; Placebo · For: Transient Insomnia
Sites: Mobile, Alabama; Phoenix, Arizona; Beverly Hills, California · 23 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Determining the Effect of an "Alternate Recovery Protocol" Versus Current Standard of Care After Cesarean SectionPivotal-lookingTerminated
Brest, Norman A., M.D.Academic, hospital or other
NCT03330119 · 1,494 participants · Start Oct 4, 2017 · Primary completion Jun 20, 2018
Drug: Alternate Management; Control · For: Pregnancy Related; Narcotic Use
Sites: Wynnewood, Pennsylvania
- A Trial to Assess Consumer Self-Selection and Use of Gabapentin for Occasional Sleeplessness in an Over-the-Counter EnvironmentPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00659100 · 1,254 participants · Start Aug 2006
Drug: Gabapentin · For: Transient Insomnia
Sites: Anaheim, California; Bonita, California; Fallbrook, California · 35 sites in all
- A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase AdvancePivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00667108 · 784 participants · Start Oct 2004
Drug: Gabapentin; Gabapentin and 1 more · For: Transient Insomnia
Sites: Anaheim, California; San Diego, California; Orlando, Florida · 8 sites in all
- A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase AdvancePivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT00666939 · 773 participants · Start Oct 2004
Drug: Gabapentin; Gabapentin and 1 more · For: Transient Insomnia
Sites: San Diego, California; Ocala, Florida; Atlanta, Georgia · 10 sites in all
- Clinical Trial of Gabapentin to Decrease Postoperative Delirium and PainPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT00221338 · 750 participants · Start Jan 2006 · Primary completion Jan 2014
Drug: Gabapentin · For: Postoperative Delirium; Postoperative Pain; Opioid Use and 1 more
Sites: San Francisco, California
- Does Gabapentin and Lamotriginel Have Significantly Fewer Side-effects While Providing Equal or Better Seizure Control Than the Current Drug Choice, Carbamazepine, for the Treatment of Seizures in the Elderly.Pivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007670 · 720 participants · Start Jan 1998
Drug: Carbamazepine; Gabapentin and 1 more · For: Seizures
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 20 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective29,887
- fatigue25,265
- nausea23,025
- pain21,365
- off label use20,051
- diarrhoea18,346
- headache18,088
- dizziness16,383
- fall15,680
- dyspnoea14,449
- vomiting12,290
- asthenia12,066
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3,727 |
| 2005 | 4,880 |
| 2006 | 4,578 |
| 2007 | 3,890 |
| 2008 | 3,697 |
| 2009 | 4,759 |
| 2010 | 7,706 |
| 2011 | 7,641 |
| 2012 | 10,961 |
| 2013 | 11,532 |
| 2014 | 14,043 |
| 2015 | 21,637 |
| 2016 | 25,871 |
| 2017 | 25,518 |
| 2018 | 30,289 |
| 2019 | 31,872 |
| 2020 | 27,335 |
| 2021 | 23,435 |
| 2022 | 22,063 |
| 2023 | 21,333 |
| 2024 | 20,663 |
| 2025 | 21,482 |
| 2026 | 15,281 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Neurontin (Gabapentin)
2024 spending
$18.6M
Beneficiaries
2,346
11,760 claims
Per beneficiary
$7,911
$8.88 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $25,573,642 |
| 2021 | $21,876,338 |
| 2022 | $20,550,126 |
| 2023 | $20,190,369 |
| 2024 | $18,559,673 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.
Hong JSW, Atkinson LZ, Al-Juffali N, et al. · Mol Psychiatry 2022 · Meta-Analysis, Systematic Review
- A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain.
Giménez-Campos MS, Pimenta-Fermisson-Ramos P, Díaz-Cambronero JI, et al. · Aten Primaria 2022 · Meta-Analysis, Systematic Review
- Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial.
Ryan NM, Birring SS, Gibson PG · Lancet 2012 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Anticonvulsants for tinnitus.
Hoekstra CE, Rynja SP, van Zanten GA, et al. · Cochrane Database Syst Rev 2011 · Meta-Analysis, Systematic Review
- The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials.
Meaadi J, Obara I, Eldabe S, et al. · Int J Clin Pharm 2023 · Meta-Analysis, Systematic Review
- Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.
Bohn E, Goren K, Switzer L, et al. · Dev Med Child Neurol 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.